308 related articles for article (PubMed ID: 25559804)
1. Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study.
Carmona-Bayonas A; Jiménez-Fonseca P; Virizuela Echaburu J; Antonio M; Font C; Biosca M; Ramchandani A; Martínez J; Hernando Cubero J; Espinosa J; Martínez de Castro E; Ghanem I; Beato C; Blasco A; Garrido M; Bonilla Y; Mondéjar R; Arcusa Lanza MÁ; Aragón Manrique I; Manzano A; Sevillano E; Castañón E; Cardona M; Gallardo Martín E; Pérez Armillas Q; Sánchez Lasheras F; Ayala de la Peña F
J Clin Oncol; 2015 Feb; 33(5):465-71. PubMed ID: 25559804
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the MASCC and CISNE scores for identifying low-risk neutropenic fever patients: analysis of data from three emergency departments of cancer centers in three continents.
Ahn S; Rice TW; Yeung SJ; Cooksley T
Support Care Cancer; 2018 May; 26(5):1465-1470. PubMed ID: 29168032
[TBL] [Abstract][Full Text] [Related]
3. Application of the MASCC and CISNE Risk-Stratification Scores to Identify Low-Risk Febrile Neutropenic Patients in the Emergency Department.
Coyne CJ; Le V; Brennan JJ; Castillo EM; Shatsky RA; Ferran K; Brodine S; Vilke GM
Ann Emerg Med; 2017 Jun; 69(6):755-764. PubMed ID: 28041827
[TBL] [Abstract][Full Text] [Related]
4. Accuracy of the Multinational Association of Supportive Care in Cancer (MASCC) and Clinical Index of Stable Febrile Neutropenia (CISNE) scores for predicting serious complications in adult patients with febrile neutropenia: A systematic review and meta-analysis.
Zheng B; Toarta C; Cheng W; Taljaard M; Reaume N; Perry JJ
Crit Rev Oncol Hematol; 2020 May; 149():102922. PubMed ID: 32244162
[TBL] [Abstract][Full Text] [Related]
5. CISNE versus MASCC: Identifying low risk febrile neutropenic patients.
Mohindra R; Mathew R; Yadav S; Aggarwal P
Am J Emerg Med; 2020 Nov; 38(11):2259-2263. PubMed ID: 31864874
[TBL] [Abstract][Full Text] [Related]
6. A nomogram for predicting complications in patients with solid tumours and seemingly stable febrile neutropenia.
Fonseca PJ; Carmona-Bayonas A; García IM; Marcos R; Castañón E; Antonio M; Font C; Biosca M; Blasco A; Lozano R; Ramchandani A; Beato C; de Castro EM; Espinosa J; Martínez-García J; Ghanem I; Cubero JH; Manrique IA; Navalón FG; Sevillano E; Manzano A; Virizuela J; Garrido M; Mondéjar R; Arcusa MÁ; Bonilla Y; Pérez Q; Gallardo E; Del Carmen Soriano M; Cardona M; Lasheras FS; Cruz JJ; Ayala F
Br J Cancer; 2016 May; 114(11):1191-8. PubMed ID: 27187687
[TBL] [Abstract][Full Text] [Related]
7. Validation of the Clinical Index of Stable Febrile Neutropenia (CISNE) model in febrile neutropenia patients visiting the emergency department. Can it guide emergency physicians to a reasonable decision on outpatient vs. inpatient treatment?
Moon H; Choi YJ; Sim SH
PLoS One; 2018; 13(12):e0210019. PubMed ID: 30596803
[TBL] [Abstract][Full Text] [Related]
8. Performance of the clinical index of stable febrile neutropenia (CISNE) in different types of infections and tumors.
Carmona-Bayonas A; Jiménez-Fonseca P; Virizuela J; Antonio M; Font C; Biosca M; Ramchandani A; Martinez-Garcia J; Hernando J; Espinosa J; de Castro EM; Ghanem I; Beato C; Blasco A; Garrido M; Mondéjar R; Arcusa MÁ; Aragón I; Manzano A; Sevillano E; Castañón E; Ayala F;
Clin Transl Oncol; 2017 Mar; 19(3):386-395. PubMed ID: 27525978
[TBL] [Abstract][Full Text] [Related]
9. Can MASCC and CISNE scores predict delays of lung cancer chemotherapy after febrile neutropenia?
Ono Y; Hayama N; Hattori S; Ito Y; Oguma T; Sakamaki F; Asano K
Thorac Cancer; 2022 Dec; 13(24):3504-3509. PubMed ID: 36330990
[TBL] [Abstract][Full Text] [Related]
10. Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network.
Hui EP; Leung LK; Poon TC; Mo F; Chan VT; Ma AT; Poon A; Hui EK; Mak SS; Lai M; Lei KI; Ma BB; Mok TS; Yeo W; Zee BC; Chan AT
Support Care Cancer; 2011 Oct; 19(10):1625-35. PubMed ID: 20820815
[TBL] [Abstract][Full Text] [Related]
11. Management of febrile neutropenia in malignancy using the MASCC score and other factors: Feasibility and safety in routine clinical practice.
Kumar P; Bajpai J; Shetty N; Medekar A; Kurkure PA; Ghadyalpatil N; Gupta S; Noronha V; Kanujia A; Parikh P; Banavali SD
Indian J Cancer; 2014; 51(4):491-5. PubMed ID: 26842174
[TBL] [Abstract][Full Text] [Related]
12. [Modalities of management of cancer patients with febrile neutropenia in the oncology emergency unit of Gustave-Roussy and their related costs].
Borget I; Antoun S; Chachaty E; Gachot B; Alibay A; Di Palma M; Merad M
Bull Cancer; 2014 Oct; 101(10):925-31. PubMed ID: 25373692
[TBL] [Abstract][Full Text] [Related]
13. Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score.
Uys A; Rapoport BL; Anderson R
Support Care Cancer; 2004 Aug; 12(8):555-60. PubMed ID: 15197637
[TBL] [Abstract][Full Text] [Related]
14. Comment on "Accuracy of the Multinational Association of Supportive Care in Cancer (MASCC) and Clinical Index of Stable Febrile Neutropenia (CISNE) scores for predicting serious complications in adult patients with febrile neutropenia: A systematic review and meta-analysis".
Ghajari H; Sabour S
Crit Rev Oncol Hematol; 2020 Nov; 155():103089. PubMed ID: 32927334
[No Abstract] [Full Text] [Related]
15. Evaluation of the clinical Index of Stable febrile neutropenia risk stratification system for management of febrile neutropenia in gynecologic oncology patients.
Monuszko KA; Albright B; Katherine Montes De Oca M; Thao Thi Nguyen N; Havrilesky LJ; Davidson BA
Gynecol Oncol Rep; 2021 Aug; 37():100853. PubMed ID: 34504931
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of complete blood count parameters to predict poor outcomes in cancer patients with febrile neutropenia presenting to the emergency department.
Choi A; Park I; Lee HS; Chung J; Kim MJ; Park YS
Ann Med; 2022 Dec; 54(1):599-609. PubMed ID: 35175159
[TBL] [Abstract][Full Text] [Related]
17. Adding procalcitonin to the MASCC risk-index score could improve risk stratification of patients with febrile neutropenia.
Ahn S; Lee YS; Lim KS; Lee JL
Support Care Cancer; 2013 Aug; 21(8):2303-8. PubMed ID: 23519568
[TBL] [Abstract][Full Text] [Related]
18. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice.
Innes H; Lim SL; Hall A; Chan SY; Bhalla N; Marshall E
Support Care Cancer; 2008 May; 16(5):485-91. PubMed ID: 17899215
[TBL] [Abstract][Full Text] [Related]
19. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications.
Klastersky J; Paesmans M; Georgala A; Muanza F; Plehiers B; Dubreucq L; Lalami Y; Aoun M; Barette M
J Clin Oncol; 2006 Sep; 24(25):4129-34. PubMed ID: 16943529
[TBL] [Abstract][Full Text] [Related]
20. The prognostic performance of adding patient-reported outcomes to the MASCC risk index to identify low-risk febrile neutropenia patients with solid tumors and lymphomas.
Wang XJ; Goh DYT; Dorajoo SR; Chan A
Support Care Cancer; 2017 Sep; 25(9):2815-2822. PubMed ID: 28401314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
